CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company discovering and developing next-generation genetic medicines, today announced its attendance at upcoming healthcare investor conferences in September and October.
Conference Details:
| Incident: | Jefferies Cell & Genetic Medicine Summit |
| Appointment time: | Thursday, 09/29th at 8:30 p.m. ET |
| Location: | New York, NY |
| Format: | company presentation |
| Incident: | Chardan 6th Annual Conference on Genetic Medicines |
| Appointment time: | Monday October 3rdapprox at 9:30 a.m. ET and 11:30 a.m. ET |
| Location: | New York, NY |
| Format: | Panel or company presentation |
| Incident: | BMO Biopharma Spotlight Series: Gene Editing & Therapeutics |
| Appointment time: | Thursday October 6thth at 12:00 p.m. ET |
| Location: | Virtual |
| Format: | blackboard |
| Incident: | Oppenheimer Private Company Showcase |
| Appointment time: | Tuesday October 18thth at 2:10 p.m. PT |
| Location: | Palo Alto, CA |
| Format: | company presentation |
A webcast of the Jefferies Cell & Genetic Medicine Summit presentation is available through the News section of the Company’s website at www.arbor.biowith a replay available 90 days after the event.
About Arbor Biotechnologies
Arbor Biotechnologies is a next generation gene editing company focused on the discovery and development of potentially curative genomic drugs. Founded by Feng Zhang, David Walt, David Scott and Winston Yan, our proprietary discovery engine focuses on discovering genetic editing capabilities ranging from knockdowns to whole gene insertion, which has enabled us to use the most extensive toolbox of proprietary genome editors in to generate the industry date each other. By using our 100% nucleases as a chassis for genetic modification, we can work backwards from disease pathology to select the optimal editing approach that specifically addresses the underlying cause of disease, resulting in potentially curative medicine for a broader spectrum of genetic disorders. As Arbor continues to advance its pipeline toward the clinic…
